Search results for "Orthohepadnavirus"

showing 10 items of 17 documents

HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy

2005

In hepatitis B virus (HBV) cirrhosis patients on long-term lamivudine (LAM), the relationships between HBV suppression, development of viral resistance and disease outcome are unclear. We analysed the dynamic of serum HBV-DNA and its relationship with the clinical course of 59 patients (52 males, mean age 51.4 ±8.4 years, 12 HBeAg positive and 47 HBeAg negative, and 57 genotype D and two genotype A) with cirrhosis (45 in Child-Turcotte-Pugh class A) and high levels of serum HBV-DNA (median 14.7x107 genomes/ml) treated with LAM [median (range): 44 (15–78) months]. A total of 50 patients (84.7%) achieved a virological response (serum HBV-DNA negative by PCR) during the first 6 months of ther…

AdultLiver CirrhosisMaleHepatitis B virusCirrhosisHBV DNA Lamivudine Therapy suppression HBV diseasemedicine.disease_causeVirus ReplicationAntiviral AgentsVirusDrug Administration ScheduleDisease courseCohort StudiesOrthohepadnavirusmedicineHumansPharmacology (medical)AgedPharmacologyHepatitis B virusbiologyReverse-transcriptase inhibitorLamivudineMiddle Agedbiology.organism_classificationmedicine.diseaseHepatitis BVirologydigestive system diseasesInfectious DiseasesHepadnaviridaeLamivudineDNA ViralMutationFemalemedicine.drug
researchProduct

Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection

2002

Abstract OBJECTIVES: The virological profiles of hepatitis B and C viruses (HBV and HCV) and their interplay in cases of coinfection are undefined. A suppressed and occult HBV infection may occur in hepatitis B surface antigen (HBsAg) negative patients with chronic hepatitis C. The HCV core protein is able to inhibit HBV “in vitro,” and serines at positions 99 and 116 are essential for such inhibition. We aimed to assess the HBV and HCV virological profiles in cases of coinfection and to evaluate the relationship between HCV core gene variability and HBV activity. METHODS: Eighty-two anti-HCV positive patients were examined: 35 cases were HBsAg positive, 24 were HBsAg negative with “occult”…

AdultMaleHepatitis B virusHBsAgHCV RNAHepacivirusHepatitis C virusDUAL INFECTION; INTERFERON THERAPY; HEPATOCELLULAR-CARCINOMA; CHRONIC LIVER-DISEASE; HCV core protein; Hepatitis B Surface Antigens; HCV RNAGenome ViralHepacivirusDUAL INFECTIONVirus Replicationmedicine.disease_causeCHRONIC LIVER-DISEASEHepatitis B ChronicINTERFERON THERAPYOrthohepadnavirusHEPATOCELLULAR-CARCINOMAmedicineHumansAgedHepatitis B virusHepatitis B Surface AntigensHepatologybiologybusiness.industryHCV core proteinGastroenterologyvirus diseasesHepatitis C ChronicMiddle AgedViral LoadHepatitis Bbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesHepadnaviridaeDNA ViralImmunologyCoinfectionRNA ViralFemalebusinessThe American Journal of Gastroenterology
researchProduct

HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines.

1999

SUMMARY The aim of this study was to examine the immunomodulating effects of rhIL-12 on the immune response induced by hepatitis B virus (HBV) antigens in clinical subgroups of patients with HBV infection. Peripheral blood mononuclear cells (PBMC) of 80 patients were stimulated with HBsAg, HBcAg, pre-S1Ag and tetanus toxoid in the absence or presence of IL-12 (0.01, 0.1 and 1 ng/ml). Stimulation by anti-CD3 + anti-CD28 and lipopolysaccharide (LPS) were used as controls. Proliferation and cytokine production were determined by 3H-thymidine uptake and ELISA after 72 h. After stimulation with HBV antigens only, production of tumour necrosis factor-alpha (TNF-α) or IL-10 was observed in all pat…

HBsAgHepatitis B virusImmunologyAntigen-Presenting CellsIn Vitro Techniquesmedicine.disease_causeLymphocyte ActivationHepatitis B AntigensInterferon-gammaHepatitis B ChronicOrthohepadnavirusmedicineImmunology and AllergyHumansHepatitis B AntibodiesHepatitisHepatitis B virusbiologybusiness.industryTumor Necrosis Factor-alphavirus diseasesOriginal ArticlesHepatitis Bmedicine.diseasebiology.organism_classificationVirologyInterleukin-12digestive system diseasesRecombinant ProteinsInterleukin-10HBcAgHBeAgHepadnaviridaeImmunologyDNA ViralLeukocytes MononuclearCytokinesInflammation MediatorsbusinessClinical and experimental immunology
researchProduct

Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplanta…

1998

“Escape” variants of hepatitis B virus (HBV) can cause infection despite previous immunization. These viruses show alterations of the immunogenic major hydrophilic loop of the HBV small surface protein (s-protein). We studied whether HBV “escape” variants were selected in patients with graft infection after liver transplantation for HBV-related diseases who received passive immunoprophylaxis with high-dose polyclonal hepatitis B hyperimmune globulin (HBIG). For that, pre- and posttransplantation sera of 34 patients were analyzed for the occurence of HBV S-gene variants. In addition, binding of in vitro–translated variant s-proteins to HBIG was studied. Variants with exchanges of amino acid …

Hepatitis B virusHepatitis B immune globulinHepatologybiologybusiness.industrymedicine.medical_treatmentLiver transplantationmedicine.disease_causebiology.organism_classificationVirologyVirusTransplantationOrthohepadnavirusHepadnaviridaeImmunologybiology.proteinMedicineAntibodybusinessmedicine.drugHepatology
researchProduct

Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B…

2009

Background The high degree of diversity of the hepatitis B virus (HBV) quasispecies in chronically infected individuals raises the possibility that HBV genetic variants favouring resistance to nucleoside/nucleotide analogues (NAs) might pre-exist to treatment. The aim of this study was to investigate the genetic variability of the entire HBV reverse transcriptase (RT) domain and of the overlapping S gene in a large series of untreated hepatitis B surface antigen carriers and in lamivudine (3TC)-resistant patients. Methods Sequencing analysis of the entire HBV RT domain of isolates from 100 untreated (treatment- naive group) and 59 3TC-resistant (3TC-resistant group) consecutive patients wit…

AdultMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaHepatitis B virusAdult; Aged; Drug Resistance; Viral; Female; Genetic Variation; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B; Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; RNA-Directed DNA Polymerase; Reverse Transcriptase Inhibitors; Sequence Analysis; DNA; Treatment OutcomeDrug ResistanceViral quasispeciesmedicine.disease_causeVirusHepatitis B ChronicOrthohepadnavirusDrug Resistance ViralmedicineHumansPharmacology (medical)ViralChronicAgedPharmacologyHepatitis B virusSettore MED/12 - GastroenterologiaHepatitis B Surface AntigensbiologyReverse-transcriptase inhibitorLamivudineGenetic VariationRNA-Directed DNA PolymeraseSequence Analysis DNADNAMiddle Agedbiology.organism_classificationHepatitis BVirologyReverse transcriptaseInfectious DiseasesTreatment OutcomeHepadnaviridaeLamivudineMutationReverse Transcriptase InhibitorsHBV reverse transcriptase gene S lamivudine resistantFemaleSequence Analysismedicine.drug
researchProduct

Selection of hepatitis B virus variants with aminoacid substitutions inside the core antigen during interferon-? therapy

2000

The hepatitis B virus (HBV) core antigen carries many epitopes relevant for B and T cell response that show aminoacid variation during viral infection. In a longitudinal analysis, sequential serum samples of 15 patients that suffered from chronic HBV infection were collected before, during, and after high-dose IFN-α treatment. The HBV preCore/Core (preC/C) sequence of the selected samples in each patient was determined and analysed for sequence variations compared to the pretreatment sample. The positions of HBV core aminoacid substitutions were assigned to immunodominant B, CD4+ and CD8+ cell epitopes. Seventy-five percent of all aminoacid substitutions were found within immunodominant T a…

Hepatitis B virusbiologyAlpha interferonmedicine.disease_causebiology.organism_classificationVirologyEpitopeVirusInfectious DiseasesAntigenOrthohepadnavirusHepadnaviridaeVirologymedicineAntigenic variationJournal of Medical Virology
researchProduct

Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or After HBs vaccination: Stimulation of thein vit…

1999

Because cellular and humoral immune responses against the hepatitis B virus (HBV) surface antigen (HBs) might be crucial to overcome HBV infection, HBs-specific B- and T-cell responses of HBV patients and HBs vaccine recipients were analyzed quantitatively and functionally. In patients with acute hepatitis B (AHB), transient high anti-HBs-secreting B-cell frequencies were observed early after clinical onset, whereas 1 patient who probably developed chronic infection and chronic HBV carriers had absent or weak B- and T-cell responses. In HBs vaccine recipients, maximal HBs-specific B- and T-cell responses were detected after the first injection that decreased gradually before anti-HBs antibo…

Hepatitis B virusHBsAgHepatologybiologybusiness.industryvirus diseasesHepatitis Bmedicine.disease_causebiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesVaccinationHepadnaviridaeAntigenOrthohepadnavirusImmunologymedicinebiology.proteinAntibodybusinessHepatology
researchProduct

Can the serological status of anti-HBc alone be considered a sentinel marker for detection of occult HBV infection?

2008

Some individuals have “occult” infection with hepatitis B virus (HBV), defined as presence of HBV genome in the serum or liver tissue without HBV surface antigen (HBsAg) in the serum. The aim of this study was to investigate whether serum antibodies against HBV core antigen in isolation (“anti-HBc alone”) are a useful marker of “occult” HBV in patients with or without hepatitis C virus (HCV) infection. “Anti-HBc alone” was detected in the sera of 119/6,544 (1.8%) asymptomatic outpatients referred to the diagnostic laboratory for routine testing for viral hepatitis, 62/607 (10.2%) drug users, and 42/195 (21.5%) patients with hepatocellular carcinoma. Using three in-house nested-PCR amplifica…

AdultMaleHBV serologic markerHBsAgHepatitis B virusGenotypeHepatitis C virusHBV genotypemedicine.disease_causeSettore MED/42 - Igiene Generale E ApplicataPolymerase Chain ReactionSensitivity and Specificity‘‘occult’’ HBVSerologyOrthohepadnavirusVirologymedicinePrevalenceHumansSerologic TestsHCCAgedHepatitis B virusAged 80 and overbiologybusiness.industryvirus diseasesSequence Analysis DNAHepatitis C AntibodiesMiddle Agedbiology.organism_classificationmedicine.diseaseHepatitis BVirologyHepatitis B Core AntigensHepatitis Cdigestive system diseasesInfectious DiseasesHepadnaviridaeImmunologyDNA Viralanti-HBcFemaleViral diseasebusinessViral hepatitisSentinel Surveillance
researchProduct

Molecular Epidemiology and Evolution in an Outbreak of Fulminant Hepatitis B Virus

2006

ABSTRACT In order to establish the transmission pathway for two outbreak patients affected by fulminant hepatitis B (FHB) following a shared period of hospitalization, we sequenced the complete genomes of the hepatitis B viruses (HBV) isolated from them as well as from the suspected common source and 11 additional controls. Phylogenetic and statistical analyses of these sequences revealed that the two FHB patients were indeed infected by a common source and that the fatal development of the disease did not appear to be associated with any mutation previously reported to be related to FHB. These data have also allowed us to estimate the extent and distribution of genetic variability along th…

Microbiology (medical)Hepatitis B virusGenome Viralmedicine.disease_causeDisease OutbreaksEvolution MolecularOrthohepadnavirusVirologymedicineHumansFulminant hepatitisLetter to the EditorPhylogenyGeneticsHepatitis B virusMolecular EpidemiologybiologyMolecular epidemiologyTransmission (medicine)OutbreakSequence Analysis DNAHepatitis BHepatitis Bbiology.organism_classificationmedicine.diseaseVirologyHepadnaviridaeDNA ViralJournal of Clinical Microbiology
researchProduct

Mosaic hepatitis B virus core particles presenting the complete preS sequence of the viral envelope on their surface

2004

The sequence of the preS domain of the hepatitis B virus (HBV, genotype D) envelope was inserted into the major immunodominant region (MIR) of the C-terminally truncated HBV core (HBc) protein. In Escherichia coli, the HBc–preS fusion protein was partially soluble and did not produce particles. Co-expression of the wild-type HBc as a helper protein along with the fusion protein led to the formation of mosaic HBc particles that exhibited HBc, preS1 and preS2 antigenicity. Two alternative combinations of medium- and high-copy plasmids were used for co-expression of fusion and helper proteins, in an attempt to improve mosaic particle production. However, the preS fusion content of the particle…

Hepatitis B virusAntigenicityvirusesAntibodies ViralProtein Engineeringmedicine.disease_causeVirusMiceViral Envelope ProteinsOrthohepadnavirusViral envelopeVirologyEscherichia colimedicineAnimalsProtein PrecursorsHepatitis B virusHepatitis B Surface AntigensbiologyViral Core Proteinsvirus diseasesProtein engineeringHepatitis Bbiology.organism_classificationVirologyFusion proteindigestive system diseasesHepadnaviridaeFemaleImmunizationReassortant VirusesPlasmidsJournal of General Virology
researchProduct